TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06644430

Intervention type: PROCEDURE
Intervention: Ablation
Description: Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.

Intervention type: DRUG
Intervention: system therapy
Description: Paticipants received systemic therapy according the instructions.

Intervention type: DRUG
Intervention: system therapy
Description: Paticipants received systemic therapy according the instructions.
Study: NCT06015646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized lifestyle coaching and educational handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
Study: NCT04805346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC®
Description: With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
Study: NCT05489224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47
Description: CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P47
Description: CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
Study: NCT06631885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regenerative endodontic procedure using blood clot according to AAE
Description: regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative endodontic procedure using photo activated nanochitosan 2%
Description: regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
Study: NCT05390645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFA-370
Description: MFA-370 is a treatment with a combination of two approved pharmaceuticals
Study: NCT05627648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KP-100LI
Description: Intracordal injection, 20 mcg once per week, 3 weeks
Study: NCT05676996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment-based support
Description: attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
Study: NCT05627648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracordal injection, once per week, 3 weeks
Study: NCT04965909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.
Description: Online group therapeutic program (small groups), applied for 3 months.
Study: NCT05194709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CAR-NK Cells
Description: The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
Study: NCT05380726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
Study: NCT06674746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLUTION FOCUSED APPROACH
Description: The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
Study: NCT06674629

Intervention type: DEVICE
Intervention: High flow oxygen therapy
Description: Application of high flow oxygen therapy through asymmetric cannula at 40 and 60 L/m
Study: NCT05683301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine + Perindopril
Description: Single pill combination of dual antihypertensive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril + Indapamide
Description: Single pill combination of dual antihypertensive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine + Indapamide
Description: Single pill combination of dual antihypertensive agent
Study: NCT06028048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLACES
Description: The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved.
Study: NCT05373719

Intervention type: OTHER
Intervention: No intervention; observational
Description: No intervention; observational

Intervention type: OTHER
Intervention: No intervention; observational
Description: No intervention; observational

Intervention type: OTHER
Intervention: No intervention; observational
Description: No intervention; observational

Intervention type: OTHER
Intervention: No intervention; observational
Description: No intervention; observational
Study: NCT06388187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT05879120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate MRgFUS + neoadjuvant pembolizumab
Description: Given by IV (vein)
Study: NCT05877560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal-Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal-Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office-Based Vergence/Accommodative Therapy
Description: Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Office-Based Vergence/Accommodative Therapy
Description: Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
Study: NCT05015478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Rhythmic Lighting Intervention
Description: 40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Rhythmic Lighting Intervention
Description: Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered at randomly varying frequencies of 20 Hz and 50 Hz, specifically avoiding the frequency of 40 Hz. The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
Study: NCT06065800

Intervention type: DEVICE
Intervention: STEELEX® Sternum Set
Description: Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
Study: NCT05499585

Intervention type: OTHER
Group type: OTHER
Intervention: Whole Dairy
Description: 2 1/2 servings of whole dairy per day
Study: NCT06584513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements
Description: The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
Study: NCT05873062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00201
Description: Single oral dose
Study: NCT06458101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter
Description: Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
Description: Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
Study: NCT05873062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study: NCT05199740

Intervention type: OTHER
Intervention: in vitro analysis
Description: in vitro analysis of mesoangioblasts from mtDNA mutation carriers
Study: NCT05787288

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Extracellular Vesicles from Mesenchymal Stem Cells
Description: Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extracellular Vesicles from Mesenchymal Stem Cells
Description: Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
Study: NCT04960800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercises
Description: Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
Study: NCT04161066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin with facilitated counseling
Description: open-label pilot study
Study: NCT04832087

Intervention type: DRUG
Intervention: Teduglutide
Description: Standard of care Teduglutide dosing

Intervention type: DRUG
Intervention: Teduglutide
Description: Standard of care Teduglutide dosing
Study: NCT06020040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heterograft
Description: Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heterograft
Description: Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
Study: NCT04522531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open cinetic chain shoulder exercise on unstabil ground
Description: Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
Study: NCT05755737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo identical in appearance.
Study: NCT05241431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: 10 mg orally once daily in addition to standard medical treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to active treatment.
Study: NCT06374771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: 10 mg of Melatonin will be given orally pre and post-operative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: 10 mg of Melatonin will be given orally pre and post-operative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1 gm of Vitamin C will be given orally pre and post-operative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1 gm of Vitamin C will be given orally pre and post-operative
Study: NCT05472324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drug is a placebo Comparator.
Study: NCT06505980

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Behavioral Parenting Program
Description: The brief behavioral parenting program is a 6 session, group-based behavioral parent training program. The components include support-building, parenting strategy education, and actively practicing parenting strategies. It is delivered through telehealth.
Study: NCT03854188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Use acupuncture therapy in the treatment of chronic pelvic pain.
Study: NCT05863273

Intervention type: DRUG
Intervention: Apremilast
Description: Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
Study: NCT05237297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: Ilaprazole 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100mg
Study: NCT06008678

Intervention type: DEVICE
Group type: OTHER
Intervention: RXiBreeze PAP System, Model RXiBreeze 20A
Description: The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.
Study: NCT05191797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT05067283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion of 200 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Per label

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Per label

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Per label
Study: NCT05962125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periodic alveolar recruitment maneuvers
Description: A stepwise increment of tidal volume was used for each ARM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodic alveolar recruitment maneuvers
Description: A stepwise increment of tidal volume was used for each ARM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive end-expiratory pressure
Description: a PEEP of 6 to 8 cm H2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive end-expiratory pressure
Description: a PEEP of 6 to 8 cm H2O
Study: NCT06414902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV